CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia

J. Levine; I. Goldberger; A. Rapaport; M. Schwartz; C. Schield; A. Elizur; R. H. Belmaker; J. Shapiro; G. Agam

doi:10.1016/0924-977X(94)90297-6

CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia

J. Levine, I. Goldberger, A. Rapaport, M. Schwartz, C. Schield, A. Elizur, R. H. Belmaker, J. Shapiro, G. Agam

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Inositol is a key metabolite in the phosphatidylinositol cycle, which is a second messenger system for serotonin-2 receptors that have been implicated in the pathophysiology of schizophrenia. Cerebrospinal fluid inositol levels were measured in 20 schizophrenic patients and 19 age- and sex-matched controls and no difference was found. However, the patients were all neuroleptic-treated. A controlled double-blind crossover trial of 12 g daily of inositol for a month in 12 anergic schizophrenic patients, twice the dose given before in schizophrenia, did not show any beneficial effects. However, the number of patients studied was small and the length of time of inositol administration may not have been sufficient.

Original language	English
Pages (from-to)	487-490
Number of pages	4
Journal	European Neuropsychopharmacology
Volume	4
Issue number	4
DOIs	https://doi.org/10.1016/0924-977X(94)90297-6
State	Published - 1 Jan 1994
Externally published	Yes

Keywords

Cerebrospinal fluid
Depression
Inositol
Schizophrenia

ASJC Scopus subject areas

Pharmacology
Neurology
Clinical Neurology
Psychiatry and Mental health
Biological Psychiatry
Pharmacology (medical)

Access to Document

10.1016/0924-977X(94)90297-6

Cite this

@article{b719b402429143419a61f1c9a39b9d76,

title = "CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia",

abstract = "Inositol is a key metabolite in the phosphatidylinositol cycle, which is a second messenger system for serotonin-2 receptors that have been implicated in the pathophysiology of schizophrenia. Cerebrospinal fluid inositol levels were measured in 20 schizophrenic patients and 19 age- and sex-matched controls and no difference was found. However, the patients were all neuroleptic-treated. A controlled double-blind crossover trial of 12 g daily of inositol for a month in 12 anergic schizophrenic patients, twice the dose given before in schizophrenia, did not show any beneficial effects. However, the number of patients studied was small and the length of time of inositol administration may not have been sufficient.",

keywords = "Cerebrospinal fluid, Depression, Inositol, Schizophrenia",

author = "J. Levine and I. Goldberger and A. Rapaport and M. Schwartz and C. Schield and A. Elizur and Belmaker, {R. H.} and J. Shapiro and G. Agam",

year = "1994",

month = jan,

day = "1",

doi = "10.1016/0924-977X(94)90297-6",

language = "English",

volume = "4",

pages = "487--490",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia

AU - Levine, J.

AU - Goldberger, I.

AU - Rapaport, A.

AU - Schwartz, M.

AU - Schield, C.

AU - Elizur, A.

AU - Belmaker, R. H.

AU - Shapiro, J.

AU - Agam, G.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Inositol is a key metabolite in the phosphatidylinositol cycle, which is a second messenger system for serotonin-2 receptors that have been implicated in the pathophysiology of schizophrenia. Cerebrospinal fluid inositol levels were measured in 20 schizophrenic patients and 19 age- and sex-matched controls and no difference was found. However, the patients were all neuroleptic-treated. A controlled double-blind crossover trial of 12 g daily of inositol for a month in 12 anergic schizophrenic patients, twice the dose given before in schizophrenia, did not show any beneficial effects. However, the number of patients studied was small and the length of time of inositol administration may not have been sufficient.

AB - Inositol is a key metabolite in the phosphatidylinositol cycle, which is a second messenger system for serotonin-2 receptors that have been implicated in the pathophysiology of schizophrenia. Cerebrospinal fluid inositol levels were measured in 20 schizophrenic patients and 19 age- and sex-matched controls and no difference was found. However, the patients were all neuroleptic-treated. A controlled double-blind crossover trial of 12 g daily of inositol for a month in 12 anergic schizophrenic patients, twice the dose given before in schizophrenia, did not show any beneficial effects. However, the number of patients studied was small and the length of time of inositol administration may not have been sufficient.

KW - Cerebrospinal fluid

KW - Depression

KW - Inositol

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0028650388&partnerID=8YFLogxK

U2 - 10.1016/0924-977X(94)90297-6

DO - 10.1016/0924-977X(94)90297-6

M3 - Article

AN - SCOPUS:0028650388

SN - 0924-977X

VL - 4

SP - 487

EP - 490

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

IS - 4

ER -

CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this